Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study

Abstract

Background: Hypertension is a common complication in patients with gout and/or hyperuricemia. Besides, hyperuricemia is a risk factor of gout as well as ischemic heart disease in hypertensive patients. Moreover, the risk of gout is modified by antihypertensive drugs. However, it remains unclear how antihypertensive agents affect uric acid metabolism.

Purpose: In the present study, we investigated the uric acid metabolism in treated hypertensive patients to find out whether any of them would influence serum levels of uric acid.

Patients and methods: 751 hypertensive patients (313 men and 438 women) under antihypertensive treatment were selected. Blood pressure (BP), serum uric acid (SUA) and serum creatinine (Scr) were measured and evaluated statistically.

Results: In patients treated with diuretics, beta-blockers and/or alpha-1 blockers SUA levels were significantly higher than in patients who were not taking these drugs. Besides, the estimated glomerular filtration rate (eGFR) in patients treated with diuretics, beta-blockers and/or alpha-1 blockers was negatively correlated with SUA level. There were gender differences in the effects of beta-blockers and alpha-1 blockers. Multiple regression analysis indicated that both diuretics and beta-blockers significantly contributed to hyperuricemia in patients with medication for hypertension.

Conclusion: Diuretics, beta-blockers and alpha-1 blockers reduced glomerular filtration rate and raised SUA levels. Calcium channel blockers, ACE inhibitors and angiotensin receptor blockers, including losartan, did not increase SUA levels.

Key words

hypertension - antihypertensive agents - hyperuricemia - gout - serum uric acid - glomerular filtration - gender difference

• References

• 1 Cannon PJ, Stason WB, Demartini FE et al. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-464
• 2 Sundatrom J, Sullivan L, D’Agostino RB et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33
• 3 Shankar A, Klein R, Klein BE et al. The association between serum uric acid level and long-term incidence of hypertension; Population-based cohort study. J Hum Hypertens 2006; 20: 937-945
• 4 Verdecchia P, Schillaci G, Reboldi G et al. Relation between serum uric acid and cardiovascular disease in essential hypertension; The PIUMA study. Hypertension 2000; 36: 1072-1078
• 5 Hoieggen A, Alderman MH, Kjeldsen SE et al., LIFE Study Group The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049
• 6 Alderman MH, Cohen H, Madhavan S et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150
• 7 Choi HK, Soriano LC, Zhang Y et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344: d8190
• 8 Choi HK, Mount DB, Roginato AM. Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516
• 9 Medical Research Council Working Party on Mild to Moderate Hypertension . Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981; 2: 539-543
• 10 Wang JG, Staessen JA, Fagard RH et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37: 1069-1074
• 11 Miyazaki S, Hamada T, Hirata S et al. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. Clin Exp Hypertens 2014; 36: 447-453
• 12 Naritomi H, Fujita T, Ito S et al. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension; The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy(J-HEALTH) study. Hypertens Res 2008; 31: 295-304
• 13 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistic. Bone Marrow Transplantation 2013; 48: 452-458
• 14 Iwaki K, Ishii M, Yonetani Y. Hypotensive and uric acid-retaining effects of trichlormethiazide under dietary sodium restriction in spontaneously hypertensive rats. Jpn J Pharmacol 1984; 36: 301-309
• 15 Houben H, Thien T, van’t Laar A. Effect of low-dose epinephrine infusion on hemodynamics after selective and nonselective beta-blockade in hypertension. Clin Pharmacol Ther 1982; 31: 685-690
• 16 Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther 1987; 1: 29-38
• 17 Leary WP, Reyes AJ, Wynne RD et al. Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects. J Int Med Res 1990; 18: 120-141
• 18 Yamamoto T, Moriwaki Y, Takahashi S et al. Effect of norepineohrine on the urinary excretion of prine bases and oxypurinol. Metabolism 2001; 50: 1230-1233
• 19 Struyker-Boudier HAJ, Janssen BJA, Smits JFM. Adrenoceptors in the kidney: Localization and pharmacology. Clin Exp Hypertems 1987; A4 (Suppl. 01) 135-150
• 20 Gonzalez-Ortiz M, Mora-Martinez JM, MartineZ-Abundis E et al. Effect of valsartan on renal handling of uric acid in healthy subjects. J Nephrol 2000; 13: 126-128
• 21 Yamanaka H. Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1018-1029
• 22 Shimamoto K. The Japanese Society of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253-390